CLINICAL TRIALS PROFILE FOR ALDOMET

All Clinical Trials for ALDOMET

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	Afshan B. Hameed, M.D.	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	University of California, Irvine	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.
NCT00580619 ↗	Autonomic Nervous System and Chronic Fatigue Syndrome	Completed	Vanderbilt University	Phase 1	2007-04-01	The investigators propose to test the hypothesis that the sympathetic nervous system contributes to the cardiovascular and inflammatory abnormalities present in the chronic fatigue syndrome (CFS) and, in particular in the subset of patients characterized by postural tachycardia syndrome (POTS). CFS and POTS are seen mostly in otherwise normal young women, and are the cause of significant disability. A substantial proportion of patients referred for evaluation of POTS met diagnostic criteria for CFS and, conversely, a subset of patients referred for treatment for CFS have POTS. The investigators hypothesize that sympathetic activation underlies the pathophysiology of patients in whom CFS and POTS overlap (CFS-P).
NCT00580619 ↗	Autonomic Nervous System and Chronic Fatigue Syndrome	Completed	Vanderbilt University Medical Center	Phase 1	2007-04-01	The investigators propose to test the hypothesis that the sympathetic nervous system contributes to the cardiovascular and inflammatory abnormalities present in the chronic fatigue syndrome (CFS) and, in particular in the subset of patients characterized by postural tachycardia syndrome (POTS). CFS and POTS are seen mostly in otherwise normal young women, and are the cause of significant disability. A substantial proportion of patients referred for evaluation of POTS met diagnostic criteria for CFS and, conversely, a subset of patients referred for treatment for CFS have POTS. The investigators hypothesize that sympathetic activation underlies the pathophysiology of patients in whom CFS and POTS overlap (CFS-P).

Clinical Trial Conditions for ALDOMET

Condition Name

Condition Name for ALDOMET
Intervention	Trials
Orthostatic Intolerance	2
Pre-eclampsia	2
Postural Tachycardia Syndrome	1
Autonomic Nervous System Diseases	1

Condition MeSH

Condition MeSH for ALDOMET
Intervention	Trials
Pre-Eclampsia	4
Eclampsia	3
Hypertension, Pregnancy-Induced	3
Hypertension	2

Clinical Trial Locations for ALDOMET

Trials by Country

Trials by Country for ALDOMET
Location	Trials
United States	4
Brazil	2
Nigeria	1
India	1
Netherlands	1

Trials by US State

Trials by US State for ALDOMET
Location	Trials
Tennessee	2
Colorado	1
California	1

Clinical Trial Progress for ALDOMET

Clinical Trial Phase

Clinical Trial Phase for ALDOMET
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for ALDOMET
Clinical Trial Phase	Trials
Completed	4
Withdrawn	2
Recruiting	1

Clinical Trial Sponsors for ALDOMET

Sponsor Name

Sponsor Name for ALDOMET
Sponsor	Trials
Vanderbilt University	2
Vanderbilt University Medical Center	2
Aga Khan University	1

Sponsor Type

Sponsor Type for ALDOMET
Sponsor	Trials
Other	17
NIH	1

Last updated: July 28, 2026

Aldomet (methyldopa) clinical trials update, market analysis, and exclusivity and patent risk projection

What is Aldomet (methyldopa) and what is its current FDA status?

Aldomet is the brand name for methyldopa (L-α-methyl-dopa), an oral antihypertensive used primarily for hypertension, including in pregnancy. Aldomet is an older small-molecule product that has extensive history of generic availability.

Featured-snippet status: Aldomet is marketed in the US primarily as a legacy brand with widespread generic substitution; today, the competitive landscape is driven by generics rather than pipeline entrants.

Regulatory reality check for market projection

• The market for methyldopa is largely volume- and cost-driven because oral generics dominate pricing.
• For clinical-trials-based upside, the key question is whether any new formulation or new indication is actively advancing in registrational trials, not whether methyldopa remains under brand-level exclusivity.

What clinical trials are ongoing or completed for methyldopa/Aldomet, and what do they imply for future launches?

Answer: For a market-driving “next-wave” in methyldopa, the trials must be registrationally relevant (new dosage form, fixed-dose combination, or new indication) and should target an FDA filing pathway (NDA/BLA, 505(b)(2), or line extensions with clinical bridging). For Aldomet specifically, the historical base is older and the commercial pathway is typically generic.

Clinical-trials implication for investors and licensees

• If trials are limited to safety or small pharmacokinetic studies, they typically do not create a pathway for meaningful incremental market share beyond existing generics.
• If trials focus on pregnancy hypertension or refinement of dosing strategies, they may support marketing claims but usually do not reset the exclusivity stack for the active ingredient.

When does Aldomet lose exclusivity, and what does that do to pricing and volumes?

Answer: Methyldopa’s active ingredient is long past brand exclusivity in most major markets. The practical driver of generic competition is not “when Aldomet loses exclusivity,” but how long any remaining patent thicket (process, polymorph, formulation, or method-of-use) can slow specific generics in narrow jurisdictions.

Market projection effect

• In legacy oral drugs, once meaningful generic entry occurs, price erosion continues through:
  • continued generic supply,
  • formulary switching,
  • and contracting by PBMs and hospital systems.
• Any residual brand retention depends on:
  • supply continuity,
  • payer preference rules,
  • and whether generics introduce bioequivalence-related switching friction.

What patents protect methyldopa/Aldomet, and how strong is the patent estate?

Answer: The patent estate for methyldopa products in 2026 is typically dominated by:

• older composition-of-matter concepts that are already expired,
• legacy patents relating to particular manufacturing processes or formulations, and
• limited method-of-use or formulation-intended improvements.

Why it matters for market projection

• For a high-volume generic oral antihypertensive, the brand’s “residual moat” is usually not a broad composition patent. It is supply- and contract-driven.
• If there are any still-active patents, they are commonly narrow and can block only specific product variants (strength, salt form, excipient system, release profile) rather than the active ingredient.

Which companies hold the market, and how does competition shape Aldomet’s revenue outlook?

Answer: The methyldopa market in the US is dominated by generic manufacturers under multiple ANDAs, with brand Aldomet generally capturing only a minority of prescriptions.

Competitive dynamics that determine price

• Generic methyldopa is a “low unit price” drug.
• Revenue growth depends on:
  • absolute volume stability (pregnancy and specific comorbidity use patterns),
  • periodic tendering and contracting,
  • and supply chain continuity.
• New entry usually yields limited incremental volume, mostly market share redistribution.

What is the generic entry risk for Aldomet, and do Paragraph IV challenges matter?

Answer: With methyldopa being a legacy active ingredient, the most relevant generic entry risks are:

• generic switches driven by bioequivalence rather than Paragraph IV,
• and potential challenges only if any still-listed Orange Book patents exist for specific strengths or formulations.

Paragraph IV relevance

• Paragraph IV matters mainly when there is an unexpired, listed patent on the Orange Book.
• For older drugs, Paragraph IV is often either absent or irrelevant because patents are expired.

What is the Orange Book status of Aldomet methyldopa products?

Answer: Aldomet’s Orange Book landscape is typically sparse in terms of active patents affecting approvals of generic methyldopa tablets.

Market projection implication

• If Orange Book listings show no active patents, then the main effect is that:
  • future competition is governed by generic economics and supply,
  • not by litigation settlements delaying entry.

How does Aldomet compare with newer antihypertensives for pregnancy and hypertension?

Answer: For pregnancy-associated hypertension and labile blood pressure management, clinicians historically used methyldopa; however, newer agents (including labetalol and nifedipine) compete for share depending on guideline evolution, tolerability, and local practice.

Commercial impact

• Even if methyldopa remains clinically used, comparative prescriber preference and guideline alignment can reduce “share of pregnant hypertensive patients.”
• That shifts market growth from “expansion” to “maintenance,” where stable demand is offset by continued substitution.

What dosing forms and formulations are commercially relevant for future demand?

Answer: Aldomet is marketed as oral tablets in the US. Future growth, if any, would more likely come from:

• lower pill burden strengths,
• improved patient handling,
• or stable supply rather than novel delivery technology.

Formulation patent relevance

• Any patent protection tied to excipient systems or release behavior typically blocks only a variant, not all methyldopa tablets broadly.
• That narrows the ability for new entrants to be delayed on litigation.

What patent litigation affects Aldomet or methyldopa generics?

Answer: For methyldopa, ongoing litigation typically occurs only if active Orange Book patents remain. In most cases, litigation risk is limited because key composition and method claims are expired.

Market projection implication

• If litigation is absent or has settled historically, future entry is usually routine and does not create major step-change revenue events.

What is the biosimilar risk for Aldomet?

Answer: None. Aldomet is a small molecule, not a biologic.

Implication for investors

• Competitive risk is generic and not biosimilar-driven.

Market analysis: base case, downside, and upside projections for Aldomet

Below is a projection framework tailored to a legacy, generic-dominated oral antihypertensive. It is deterministic on supply and substitution rather than on a late-stage pipeline.

Base case (most likely)

• Volume stays largely stable due to established use cases (including pregnancy).
• Price continues to erode or remains low due to generic competition.
• Revenue tracks modestly with overall hypertension treatment volumes and prescribing patterns.
• Any brand maintenance is driven by contracting and supply continuity.

Projection posture: flat-to-slightly declining revenue in real terms; no meaningful growth catalyst from clinical pipeline.

Downside case

• Continued guideline-driven substitution away from methyldopa for pregnancy hypertension reduces share.
• Formularies tighten toward first-line preferred agents.
• Supply consolidation leads to sporadic availability issues that can shift patients temporarily but may not restore brand share.

Projection posture: low-to-moderate revenue contraction; increased volatility due to contracting behavior.

Upside case

• New dosing preferences, improved tolerability evidence in specific subpopulations, or renewed pregnancy protocol adoption increases relative use.
• A durable new formulation line extension captures incremental share without needing broad exclusivity.

Projection posture: limited upside, constrained by generic substitution and low pricing elasticity.

What would drive a step-change in value for Aldomet?

A meaningful valuation step-change requires one of the following:

• a new registrational-quality clinical program leading to a new indication or label expansion that materially increases treatable patient pool,
• a proprietary formulation with a still-active exclusivity/patent position that blocks direct generic equivalents for a period,
• or a major supply event that reduces generic availability and increases brand visibility (rare and temporary).

For methyldopa, none of these are typical of legacy oral markets unless there is a fresh, defensible product strategy.

Key Takeaways

• Aldomet (methyldopa) is a legacy oral antihypertensive where the market is primarily shaped by generic substitution, contracting, and guideline-driven prescribing rather than by an active brand pipeline.
• Clinical-trials value for future growth depends on registrational relevance; smaller PK or safety work typically does not create a durable exclusivity-driven commercial moat.
• Exclusivity and patent impact in 2026 is usually limited; when Orange Book listings have no active patents, generic competition is largely unblocked by litigation.
• Revenue outlook is best modeled as volume-stability with ongoing low pricing, with upside constrained unless there is a new defensible formulation strategy or label expansion.

FAQs

1. Are there any new registrational trials for methyldopa that could support an NDA or major label expansion?
2. Do any Orange Book patents still block generic methyldopa tablets in the US for specific strengths?
3. How do guideline shifts for pregnancy hypertension affect methyldopa prescribing share versus labetalol and nifedipine?
4. What supply and contracting dynamics most influence methyldopa pricing and pharmacy utilization?
5. Is there any credible reformulation strategy for methyldopa (dose simplification or stability improvements) that can create exclusivity?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/